Dataset Information

Identification of recombinant settlement-inducing protein complex from Amphibalanus amphitrite by LC-MS/MS

ABSTRACT: Settlement-inducing protein complex (SIPC) is a protein that acts as a phoromone cue to attract conspecific of the barnacle Amphibalanus amphitrite to settle on a substrate. Recombinant settlement-inducing protein complex was expressed in insect Sf9 cells through a baculovirus overexpression system, purified and analysed by mass spectrometry to confirm its identity.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Amphibalanus Amphitrite (striped Barnacle) (balanus Amphitrite) Insecta

SUBMITTER: Skarlatos Dedos

LAB HEAD: Skarlatos G. Dedos

PROVIDER: PXD006858 | Pride | 2019-01-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	12091401.mgf	Mgf
	12091401.pride.mgf.gz	Mgf
	Kotsiri et al. 2017-SIPC analysis by LC-MS:MS.pride.mztab.gz	Mztab
	Kotsirietal.2017-SIPCanalysisbyLC-MSMS.msf	Msf
	Kotsirietal.2017-SIPCanalysisbyLC-MSMS.mzid.gz	Mzid

Items per page:

1 - 5 of 7

Publications

Should I stay or should I go? The settlement-inducing protein complex guides barnacle settlement decisions.

Kotsiri Manto M Protopapa Maria M Mouratidis Sofoklis S Zachariadis Michael M Vassilakos Demetrios D Kleidas Ioannis I Samiotaki Martina M Dedos Skarlatos G SG

The Journal of experimental biology 20181120 Pt 22

Reproduction in barnacles relies on chemical cues that guide their gregarious settlement. These cues have been pinned down to several sources of settlement pheromones, one of which is a protein termed settlement-inducing protein complex (SIPC), a large glycoprotein acting as a pheromone to induce larval settlement and as an adhesive in surface exploration by the cyprids. Settlement assays in laboratory conditions with Amphibalanus (=Balanus) amphitrite cyprids in the presenc ...[more]

PMID: 30291158

Similar Datasets

Project description:PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation. Glioblastoma (GBM) is the most common and lethal brain tumor in adults. Ionizing radiation (IR) is a standard treatment for GBM patients and results in DNA damage. However, the clinical efficacy of IR is limited due to therapeutic resistance. The programmed death ligand 1 (PD-L1) blockade has a shown the potential to increase the efficacy of radiotherapy by inhibiting DNA damage and repair responses. The miR-33a-5p is an essential microRNA that promotes GBM growth and self-renewal. In this study, we investigated whether a PD-L1 inhibitor (a small molecule inhibitor) exerted radio-sensitive effects to impart an anti-tumor function in GBM cells by modulating miR-33a-5p. U87 MG cells and U251 cells were pretreated with PD-L1 inhibitor. The PD-L1 inhibitor-induced radio-sensitivity in these cells was assessed by assaying cellular apoptosis, clonogenic survival assays, and migration. TargetScan and luciferase assay showed that miR-33a-5p targeted the phosphatase and tensin homolog (PTEN) 3' untranslated region. The expression level of PTEN was measured by western blotting, and was also silenced using small interfering RNAs. The levels of DNA damage following radiation was measured by the presence of γ-H2AX foci, cell cycle, and the mRNA of the DNA damage-related genes, BRCA1, NBS1, RAD50, and MRE11. Our results demonstrated that the PD-L1 inhibitor significantly decreased the expression of the target gene, miR-33a-5p. In addition, pretreatment of U87 MG and U251 cells with the PD-L1 inhibitor increased radio-sensitivity, as indicated by increased apoptosis, while decreased survival and migration of GBM cells. Mir-33a-5p overexpression or silencing PTEN in U87 MG and U251 cells significantly attenuated PD-L1 radiosensitive effect. Additionally, PD-L1 inhibitor treatment suppressed the expression of the DNA damage response-related genes, BRCA1, NBS1, RAD50, and MRE11. Our results demonstrated a novel role for the PD-L1 inhibitor in inducing radio- sensitivity in GBM cells, where inhibiting miR-33a-5p, leading to PTEN activated, and inducing DNA damage was crucial for antitumor immunotherapies to treat GBM.